Sanofi Partnership On Oral IL-17 Could Be Turning Point For C4XD
May Validate Small Molecule Platform
Executive Summary
The UK drug discovery specialist has made slow progress until now, but the Sanofi deal could yield a challenger in the competitive psoriasis field.
You may also be interested in...
Bristol Lays Groundwork For First Dermatology Launch, Ahead Of TYK2 Inhibitor
The company has not even filed the TYK2 inhibitor deucravacitinib for psoriasis, but Bristol will be a new player in a category dominated by entrenched rivals.
Sanofi Adds mRNA Specialist Tidal To Acquisition Spree
Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.
Sanofi Sees Booster Role For Covid Vaccine After Solid But Underwhelming Results
Once expected to play a key role in beating COVID-19, Sanofi and GSK now see their vaccine as most likely to be used as a booster.